Bipolar Disorders in Saudi Arabia: What Do We Know So Far?

被引：0

作者：

Almadani, Ahmad H. ^{[1
,2
]}

Alhadi, Ahmad N. ^{[1
,2
,3
]}

Aldawood, Buthainah D. ^{[4
]}

Aleissa, Mariam M. ^{[5
,6
]}

Alosaimi, Fahad D. ^{[1
,2
]}

机构：

[1] King Saud Univ, Coll Med, Dept Psychiat, Riyadh, Saudi Arabia

[2] King Saud Univ, King Saud Univ Med City, Dept Psychiat, Riyadh, Saudi Arabia

[3] King Saud Univ, Coll Med, SABIC Psychol Hlth Res & Applicat Chair, Riyadh, Saudi Arabia

[4] Princess Nourah bint Abdulrahman Univ, Coll Hlth & Rehabil Sci, Dept Clin Psychol, Riyadh, Saudi Arabia

[5] Publ Hlth Lab, Dept Mol Genet, Publ Hlth Author, Riyadh, Saudi Arabia

[6] Alfaisal Univ, Med Sch, Riyadh, Saudi Arabia

来源：

SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES | 2025年 / 13卷 / 01期

关键词：

Bipolar disorders; clinical manifestations; epidemiology; etiology; psychotropic medications; Saudi Arabia; OUTPATIENT PSYCHIATRIC SETTINGS; PREVALENCE; PATTERNS; INPATIENT; DIAGNOSES; STIGMA;

D O I：

10.4103/sjmms.sjmms_306_24

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bipolar disorders (BP) are prevalent neuropsychiatric illnesses affecting 1%-5% of the global population and about 3% of the Saudi population. They are associated with significant comorbidities and negative consequences. Despite being common mental health conditions in Saudi Arabia, stigma persists, with weak character, supernatural beliefs, and weak faith considered as causes. In addition, Saudi patients with BP have been reported to seek help from non-psychiatric healthcare professionals and faith healers. More data are required on BP from Saudi Arabia, including the genetic aspects and their treatment approaches. This narrative review paper explores the epidemiology and clinical manifestations, etiology and biological mechanisms, public knowledge and awareness of the illnesses, and treatment of BP in Saudi Arabia.

引用

页码：1 / 6

页数：6

共 50 条

[41] Bladder Cancer and Probiotics: What Do We Know So Far?
Sanchez-Pellicer, Pedro
Boix-Rodriguez, Claudia
Hernandez-Belmonte, Adriana
de la Encarnacion-Castellano, Cristina
Mendiola-Lopez, Alberto
Nunez-Delegido, Eva
Navarro-Moratalla, Laura
Aguera-Santos, Juan
Navarro-Lopez, Vicente
Galan-Llopis, Juan Antonio
CANCERS, 2023, 15 (23)
[42] Thirst in heart failure: what do we know so far?
Allida, Sabine M.
Hayward, Christopher S.
Newton, Phillip J.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (01) : 4 - 9
[43] Genetics and Epigenetics in Obesity: What Do We Know so Far?
Maria Keller
Stina Ingrid Alice Svensson
Kerstin Rohde-Zimmermann
Peter Kovacs
Yvonne Böttcher
Current Obesity Reports, 2023, 12 (4) : 482 - 501
[44] Relationships and networks in context: what do we know so far?
ALHussan, Fawaz Baddar
Batt, Peter J.
Al-Husan, Faten Baddar
JOURNAL OF BUSINESS & INDUSTRIAL MARKETING, 2021, 36 (11) : 1957 - 1961
[45] BARIATRIC SURGERY IN ADOLESCENTS: WHAT DO WE KNOW SO FAR?
Beamish, A. J.
Johansson, S. E.
Olbers, T.
SCANDINAVIAN JOURNAL OF SURGERY, 2015, 104 (01) : 24 - 32
[46] What Do We Know So Far about Multigenerational Mobility?
Solon, Gary
ECONOMIC JOURNAL, 2018, 128 (612): : F340 - F352
[47] COVID-19 in Children With Blood and Cancer Disorders: What Do We Know So Far?
Yadav, Satya P.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2020, 42 (06) : 413 - 414
[48] Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far?
Lemes, Luciana Rodino
Melo, Daniel Fernandes
de Oliveira, Daniele Sguissardi
de La-Rocque, Marcella
Zompero, Camila
Ramos, Paulo Mueller
DERMATOLOGIC THERAPY, 2020, 33 (06)
[49] Biological Indicators of Suicide Risk in Youth With Mood Disorders: What Do We Know So Far?
Ute Lewitzka
Sarah Doucette
Florian Seemüller
Paul Grof
Anne C. Duffy
Current Psychiatry Reports, 2012, 14 : 705 - 712
[50] A systematic review on the comorbidity between premenstrual and mood disorders: What do we know so far?
Bengi, Deniz
Strawbridge, Rebecca
Drorian, Melisa
Juruena, Mario
Young, Allan H.
Frey, Benicio N.
Yalin, Nefize
BIPOLAR DISORDERS, 2024, 26 : 106 - 106

← 1 2 3 4 5 →